Pathway Genomics' ColoTrue and LynchSyndromeTrue
Pathway Genomics announced it has launched ColoTrue, a comprehensive panel that combines next-generation sequencing with deletion/duplication analysis to detect pathogenic variants in 15 high-risk colorectal cancer susceptibility genes. Pathway has also launched a smaller five-gene panel, LynchSyndromeTrue, which tests genes associated with Lynch syndrome, the most common form of hereditary colon cancer.
Agena Bioscience's LungFUSION Panel
Agena Bioscience has released its LungFUSION Panel for rapid and sensitive identification of oncogenic ALK, RET, and ROS1 gene fusions in non-small cell lung cancer tumors. The panel contains built-in controls to simultaneously assess RNA quality, report DNA contamination, and determine the relative amount of lung tissue present in the sample. It runs on the firm's MassArray platform, which detects genetic variation directly by end-point PCR and label-free mass spectrometry.
Cypher Genomics' Mantis
Cypher Genomics has released a new software update to automate the interpretation of sequencing data from cancer genomes. With the update, Cypher's Mantis technology will now provide rapid insight into how different genetic variants may impact cancer progression and therapeutic effectiveness, the company said. The update will also provide a summary of somatic and germline variants for single nucleotide variants and small indels, as well as resolve difficult-to-classify variants of unknown significance.
For more recently launched products and services, please see the New Products page on our website.